A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 68
- Registration Number
- NCT02133001
A Pharmacokinetic, Safety and Tolerability Study of Esketamine in Healthy Elderly and Adult Participants
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT02129088
A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 101
- Registration Number
- NCT02127593
A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Formulation 2Drug: Formulation 1
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT02117505
Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study
Completed
- Conditions
- Plaque, AmyloidAlzheimer's Disease
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1136
- Registration Number
- NCT02114372
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Phase 3
Completed
- Conditions
- Rheumatic DiseasesHeart FailureRespiratory InsufficiencyStroke AcuteInfectious Diseases
- Interventions
- Drug: Rivaroxaban, 10 mgDrug: PlaceboDrug: Rivaroxaban, 7.5 mg
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12024
- Registration Number
- NCT02111564
A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02094378
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Phase 1
Completed
- Conditions
- Psychotic DisordersSchizophreniaBipolar DisorderDepressive Disorder
- Interventions
- Drug: Aripiprazole, oral formulationDrug: Olanzapine, oral formulationDrug: Paliperidone, oral formulationDrug: Quetiapine, oral formulationDrug: Risperidone, oral formulationDrug: Paliperidone, LAIDrug: Risperidone, LAI
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 305
- Registration Number
- NCT02087579
A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: DOXIL/CAELYX reference product (Treatment A)Drug: DOXIL/CAELYX test product (Treatment B)
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT02081495
Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 144
- Registration Number
- NCT02079545
© Copyright 2025. All Rights Reserved by MedPath